tetano
Editor, Senior Moderator
Adv Sci (Weinh)
. 2020 Oct 24;2002928.
doi: 10.1002/advs.202002928. Online ahead of print.
Biomimetic Human Disease Model of SARS-CoV-2 Induced Lung Injury and Immune Responses on Organ Chip System
Min Zhang[SUP] 1 2 [/SUP], Peng Wang[SUP] 1 [/SUP], Ronghua Luo[SUP] 3 4 5 [/SUP], Yaqing Wang[SUP] 1 2 [/SUP], Zhongyu Li[SUP] 1 [/SUP], Yaqiong Guo[SUP] 1 2 [/SUP], Yulin Yao[SUP] 4 6 [/SUP], Minghua Li[SUP] 3 [/SUP], Tingting Tao[SUP] 1 2 [/SUP], Wenwen Chen[SUP] 1 2 [/SUP], Jianbao Han[SUP] 3 [/SUP], Haitao Liu[SUP] 1 2 [/SUP], Kangli Cui[SUP] 1 2 [/SUP], Xu Zhang[SUP] 1 [/SUP], Yongtang Zheng[SUP] 3 4 5 [/SUP], Jianhua Qin[SUP] 1 7 8 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The models that can accurately resemble human-relevant responses to viral infection are lacking. Here, we create a biomimetic human disease model on chip that allows to recapitulate lung injury and immune responses induced by SARS-CoV-2 in vitro at organ level. This human alveolar chip reproduced the key features of alveolar-capillary barrier by co-culture of human alveolar epithelium, microvascular endothelium and circulating immune cells under fluidic flow in normal and disease. Upon SARS-CoV-2 infection, the epithelium exhibited higher susceptibility to virus than endothelium. Transcriptional analyses showed activated innate immune responses in epithelium and cytokine-dependent pathways in endothelium at 3 days post-infection, revealing the distinctive responses in different cell types. Notably, viral infection caused the immune cell recruitment, endothelium detachment, and increased inflammatory cytokines release, suggesting the crucial role of immune cells involving in alveolar barrier injury and exacerbated inflammation. Treatment with remdesivir could inhibit viral replication and alleviate barrier disruption on chip. This organ chip model can closely mirror human-relevant responses to SARS-CoV-2 infection, which is difficult to be achieved by in vitro models, providing a unique platform for COVID-19 research and drug development. This article is protected by copyright. All rights reserved.
Keywords: COVID‐19; SARS‐CoV‐2; disease model; drug testing; organ chip.
. 2020 Oct 24;2002928.
doi: 10.1002/advs.202002928. Online ahead of print.
Biomimetic Human Disease Model of SARS-CoV-2 Induced Lung Injury and Immune Responses on Organ Chip System
Min Zhang[SUP] 1 2 [/SUP], Peng Wang[SUP] 1 [/SUP], Ronghua Luo[SUP] 3 4 5 [/SUP], Yaqing Wang[SUP] 1 2 [/SUP], Zhongyu Li[SUP] 1 [/SUP], Yaqiong Guo[SUP] 1 2 [/SUP], Yulin Yao[SUP] 4 6 [/SUP], Minghua Li[SUP] 3 [/SUP], Tingting Tao[SUP] 1 2 [/SUP], Wenwen Chen[SUP] 1 2 [/SUP], Jianbao Han[SUP] 3 [/SUP], Haitao Liu[SUP] 1 2 [/SUP], Kangli Cui[SUP] 1 2 [/SUP], Xu Zhang[SUP] 1 [/SUP], Yongtang Zheng[SUP] 3 4 5 [/SUP], Jianhua Qin[SUP] 1 7 8 2 [/SUP]
Affiliations
- PMID: 33173719
- PMCID: PMC7646023
- DOI: 10.1002/advs.202002928
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The models that can accurately resemble human-relevant responses to viral infection are lacking. Here, we create a biomimetic human disease model on chip that allows to recapitulate lung injury and immune responses induced by SARS-CoV-2 in vitro at organ level. This human alveolar chip reproduced the key features of alveolar-capillary barrier by co-culture of human alveolar epithelium, microvascular endothelium and circulating immune cells under fluidic flow in normal and disease. Upon SARS-CoV-2 infection, the epithelium exhibited higher susceptibility to virus than endothelium. Transcriptional analyses showed activated innate immune responses in epithelium and cytokine-dependent pathways in endothelium at 3 days post-infection, revealing the distinctive responses in different cell types. Notably, viral infection caused the immune cell recruitment, endothelium detachment, and increased inflammatory cytokines release, suggesting the crucial role of immune cells involving in alveolar barrier injury and exacerbated inflammation. Treatment with remdesivir could inhibit viral replication and alleviate barrier disruption on chip. This organ chip model can closely mirror human-relevant responses to SARS-CoV-2 infection, which is difficult to be achieved by in vitro models, providing a unique platform for COVID-19 research and drug development. This article is protected by copyright. All rights reserved.
Keywords: COVID‐19; SARS‐CoV‐2; disease model; drug testing; organ chip.